Wendeng Central Hospital of Weihai

of Weihai, China

Wendeng Central Hospital of Weihai

of Weihai, China

Time filter

Source Type

Zhang Y.,Hubei University of Medicine | Huang J.,National Hospital of Enshi Autonomous Prefecture | Wang P.,Wendeng Central Hospital of Weihai
Medicine (United States) | Year: 2016

We aim to build models for peripheral arterial disease (PAD) risk prediction and seek to validate these models in 2 different surveys in the US general population. Model building survey was based on the National Health and Nutrition Examination Surveys (NHANES, 1999-2002). Potential predicting variables included race, gender, age, smoking status, total cholesterol (TC), body mass index, high-density lipoprotein (HDL), ratio of TC to HDL, diabetes status, HbA1c, hypertension status, and pulse pressure. The PAD was diagnosed as ankle brachial index <0.9. We used multiple logistic regression method for the prediction model construction. The final predictive variables were chosen based on the likelihood ratio test. Model internal validation was done by the bootstrap method. The NHANES 2003-2004 survey was used for model external validation. Age, race, sex, pulse pressure, the ratio of TC to HDL, and smoking statuswere selected in the final predictionmodel. The odds ratio (OR) and 95% confidence interval (CI) for age with 10 years increase was 2.00 (1.72, 2.33), whereas that of pulse pressure for 10mm Hg increase was 1.19 (1.10, 1.28). TheOR of PADwas 1.11 (95%CI: 1.02, 1.21) for 1 unit increase in the TC to HDL ratio and was 1.61 (95% CI: 1.40, 1.85) for people who were currently smoking compared with those who were not. The respective area under receiver operating characteristics (AUC) of the final model from the training survey and validation survey were 0.82 (0.82, 0.83) and 0.76 (0.72, 0.79) indicating good model calibrations. Our model, to some extent, has a moderate usefulness for PAD risk prediction in the general US population. © 2016 Wolters Kluwer Health, Inc. All rights reserved.


Yu T.,University of Sichuan | Wu Y.,University of Sichuan | Huang Y.,University of Sichuan | Yan C.,University of Sichuan | And 6 more authors.
Molecular Therapy | Year: 2012

CXC chemokine receptor 4 (CXCR4) is involved in many human malignant tumors and plays an important role in tumor growth and metastasis. To explore the effects of CXCR4 expression on the malignant cells of oral squamous cell carcinoma (OSCC), Tca8113 and SCC-9 cell lines, as well as their xenograft models, of nude mice were used to detect cancer cell proliferation alteration. This study also examined the corresponding molecular mechanism after CXCR4 knockdown using a recombinant lentiviral vector expressing small interference RNA (siRNA) for CXCR4. RNA interference-mediated knockdown of CXCR4 in highly aggressive (Tca8113 and SCC-9) tumor cells significantly inhibited the proliferation of the two cell lines in vitro and in vivo. The expression levels of >1,500 genes involved in cell cycle, apoptosis, and multiple signaling pathways were also altered. These results provide new evidence of CXCR4 as a promising tumor gene therapeutic target. © The American Society of Gene & Cell Therapy.


Man H.B.,Wendeng Central Hospital of Weihai | Bi W.P.,Wendeng Central Hospital of Weihai | Man H.H.,Wendeng Central Hospital of Weihai
Genetics and Molecular Research | Year: 2016

Previous evidence has shown the association of aberrant miR-198 expression with tumorigenesis and progression of many human malignancies. However, its involvement in human glioma is still unclear. Therefore, the aim of the current study was to investigate the expression and function of miR-198 in human gliomas. Using real-time quantitative RT-PCR, we examined miR-198 expression in 122 pairs of human gliomas and matched non-neoplastic brain tissues. The association of miR-198 expression with clinicopathological factors was also analyzed. Then, the effects of miR-198 on the biological behavior of glioma cells in vitro were evaluated. Our results showed that miR-198 expression was significantly downregulated in gliomas compared with corresponding non-neoplastic brain tissues (P < 0.001). Furthermore, low levels of miR-198 were associated with a higher WHO grade and lower Karnofsky performance status (KPS) score. A multivariate Cox regression analysis identified decreased miR-198 expression as an independent factor predicting poor prognosis for glioma patients. Lastly, in vitro functional analysis revealed that overexpression of miR- 198 in U87 cells reduced cell proliferation, promoted cell apoptosis, and inhibited cell invasion and migration. Taken together, these findings indicate that miR-198 may act as a tumor suppressor in human glioma, and may serve as a novel target for molecular therapies of this disease. © FUNPEC-RP.


Wang X.,Wendeng Central Hospital of Weihai | Xia M.,Wendeng Central Hospital of Weihai
Journal of Receptors and Signal Transduction | Year: 2015

5-Hydroxy-3,6,7,8,3′,4′-hexamethoxyflavone (5HHMF), a polymethoxyflavone (PMF) mainly found in citrus plants, exhibits excellent physiological functions. In this study, we aimed to investigate the anticancer activity of 5HHMF against human gastric cancer cell BGC-7901 both in vitro and in vivo and illustrate the potential mechanisms. The proliferation of BGC-7901 cells was assessed by MTT assay. Reactive oxygen species (ROS) level was determined by ELISA kit. The protein expression was determined by western blot analysis. Antitumor activity of 5HHMF in vivo was evaluated in BALB/c nude mice. The results showed that treatment with 5HHMF significantly suppressed BGC-7901 cells proliferation, increased ROS generation, and upregulated cytochrome c release from the mitochondria to the cytosol. Western blot analysis demonstrated that 5HHMF significantly downregulated the expression of procaspase-3, procaspase-9, and PARP and upregulated cleaved caspase-3, cleaved caspase-9, cleaved PARP, and Bax/Bcl-2 ratio. Meanwhile, 5HHMF treatment markedly decreased the expression of PI3K and p-Akt. In addition, 5HHMF effectively inhibited tumor growth in xenograft models in BALB/c nude mice without major side action. In summary, 5HHMF-induced apoptosis via targeting PI3K/Akt, indicating 5HHMF is a potential antitumor agent for gastric cancer. © 2015 Taylor & Francis.


Wang B.,Wendeng Central Hospital of Weihai | Xu C.,Wendeng Central Hospital of Weihai
International Journal of Clinical and Experimental Medicine | Year: 2016

Multidrug resistance (MDR) represents a major challenge for successful chemotherapeutic treatment of cancer. Resveratrol (RES) is believed to have multiple bioactivities including anti-cancer, prevention of cardiovascular diseases, and anti-inflammatory. This study was aimed to examine the effect of resvertrol on human leukemic MDR K562/A02 cells. Treatment of combination of resveratrol and adriamycin (ADM) resulted in potentiation of cytotoxicity detected using a cell counting kit-8 assay, and treatment with a combination of RES and ADM caused synergistic enhancement of the proliferation inhibition effect. RES increased Rh123 retention and ADM accumulation in K562/A02 cells. Furthermore, the combined treatment of RES and ADM synergistically delayed the growth of xenografts in mice. In addition, the expression of P-glycoprotein (p-gp) was significantly decreased following treatment with resveratrol alone or in combination with ADM both in vitro and in vivo. These findings demonstrated that resveratrol is important in MDR and may be developed into a new reversal agent for cancer chemotherapy. © 2016, E-Century Publishing Corporation. All rights reserved.


Wang X.-X.,Wendeng Central Hospital of Weihai | Wang H.-Y.,Xuzhou Medical College | Zheng J.-N.,Xuzhou Medical College | Sui J.-C.,Wendeng Central Hospital of Weihai
Journal of Cancer Research and Therapeutics | Year: 2014

Primary cutaneous sweat gland carcinoma is a rare neoplasm of malignant sweat gland lesions. It is characterized clinically with non-symptomatic, slow-growing nodules. We report the case of a patient with cutaneous sweat gland carcinoma with local recurrence and metastasis to the lung that was treated with surgical resection therapy and chemotherapy. The initial neoplasm was excised but biopsy was not performed. The tumor then recurred 7 years later, was re-excised, biopsy was performed, and diagnosed as a low-grade hidradenocarcinoma. We presented a very good result of chemotherapy in the treatment of this rare malignant disease. It demonstrates that adjunct chemotherapy is effective to control the condition of malignant sweat-gland carcinomas patient.


Wang B.,Wendeng Central Hospital of Weihai | Liu J.,Wendeng Central Hospital of Weihai | Gong Z.,Wendeng Central Hospital of Weihai
International Journal of Clinical and Experimental Medicine | Year: 2015

Resveratrol, an edible polyphenolic phytoalexin obtained primarily from root extracts of the oriental plant, Polygonum cuspidatum and from grapes and red wine, has been reported as an anticancer compound against several types of cancer, the accurate molecular mechanisms of by which it induces apoptosis are limited. In the present study, the molecular mechanisms of resveratrol on human leukemia K562 cells apoptosis was examined. Our results showed that resveratrol significantly decreased cell viability and triggered cell apoptosis in K562 cells. Resveratrol-induced apoptosis of K562 cells was associated with the dissipation of mitochondrial membrane potential (MMP) and the release of cytochrome c into the cytosol. Furthermore, the up-regulation of Bax/Bcl-2 ratio, the activation of caspase-3 and increased cleaved PARP was also observed in K562 cells treated with resveratrol. Thus, we considered that the resveratrol-induced apoptosis of K562 cells might be mediated through the mitochondria pathway, which gives the rationale for in vivo studies on the utilization of resveratrol as a potential cancer therapeutic compound. © 2015, E-Century Publishing Corporation. All rights reserved.


Wang K.,Shandong University | Ma W.,Shandong University | Wang J.,Shandong University | Yu L.,Affiliated Hospital of Binzhou Medical College | And 9 more authors.
Journal of Thoracic Oncology | Year: 2012

OBJECTIVE:: Tumor-stroma ratio (TSR) has been identified as a new and practicable prognostic histological characteristic of solid tumors. The aim of this study was to evaluate the prognostic value of TSR in resected esophageal squamous cell carcinoma (ESCC). METHODS:: A total of 95 patients who underwent esophagectomy for ESCC were included in this study. TSR was assessed visually on the hematoxylin-eosin-stained tissue sections of surgical specimens by two independent observers. Patients with more than 50% intratumor stroma were quantified as the stroma-rich group and those with less than 50% as the stroma-poor group. RESULTS:: No significant differences were observed in patient, tumor, and treatment characteristics between the stroma-rich and stroma-poor groups. The 3-year overall survival and disease-free survival rates were 64% and 57%, respectively, in the stroma-poor group, and 23% and 23%, respectively, in the stroma-rich group. Both 3-year overall and disease-free survival rates in the stroma-poor group were significantly better than those in the stroma-rich group (p < 0.01). In a multivariate analysis, TSR was identified as a highly significant prognostic factor for 3-year overall survival (hazard ratio 3.450; p = 0.001) and 3-year disease-free survival (hazard ratio 2.995; p = 0.001), independent of pTNM stage and radicality of the primary tumor. CONCLUSION:: Stroma-rich tumors were associated with poor prognosis and an increased risk of relapse, which may serve as a new prognostic histological characteristic in ESCC. TSR is simple and quick to determine, is reproducible, and could be easily incorporated in routine histological evaluation. © 2012 by the International Association for the Study of Lung.


Wang X.J.,Wendeng Central Hospital of Weihai | Xia M.,Wendeng Central Hospital of Weihai | Bi W.P.,Wendeng Central Hospital of Weihai
Genetics and Molecular Research | Year: 2016

Dysregulation of miRNAs is associated with cancer development and progression. For example, aberrant expression of miR-874 has been found in some types of cancer. However, miR-874 expression and its clinical significance in colorectal cancer (CRC) have not yet been explored. The aim of the current study was to explore the effects of miR-874 in CRC tumorigenesis and development. Quantitative reverse-transcription PCR was performed to evaluate miR-874 levels in CRC cell lines and in 135 pairs of primary human CRC specimens and adjacent noncancerous tissues. The association of miR-874 expression with clinicopathological factors and prognosis was also analyzed. Furthermore, the effects of miR-874 on the biological behavior of CRC cells in vitro were investigated. Our results revealed that miR-874 expression was significantly downregulated in CRC cancer tissues and cell lines. Decreased miR-874 expression was significantly associated with larger tumor size, deeper invasion depth, and advanced TNM stage in vivo. Additionally, low miR-874 expression in CRC was an independent predictor of poor survival. Moreover, overexpression of miR-874 inhibited cell proliferation, invasion, and migration, and promoted cell apoptosis of the SW620 CRC cell line in vitro. Taken together, these findings indicate that miR-874 may act as a tumor suppressor in CRC, and may serve as a novel therapeutic target for miR-based therapy. © FUNPEC-RP.


Wang X.-X.,Wendeng Central Hospital of Weihai | Liu H.-Q.,Wendeng Central Hospital of Weihai | Sui J.-C.,Wendeng Central Hospital of Weihai
American Journal of Therapeutics | Year: 2016

Distal bone metastases from rectal cancer are uncommon. Our case report is from a patient with rectal carcinoma who presented with symptomatic middle finger metastases, and we describe the clinical characteristics of this presentation and the treatment provided. Metastases in bone tissues are a sign of a grave prognostic outcome due to the association of this with advanced terminal disease. Palliative treatment for symptom relief is the only option in this situation. © 2014 Wolters Kluwer Health, Inc.

Loading Wendeng Central Hospital of Weihai collaborators
Loading Wendeng Central Hospital of Weihai collaborators